Pro-inflammatory cytokines and their receptors in chronic heart failure: Do they really matter?

Acta Cardiologica

Volumn 61, Issue 2, 2006, Pages 161-168

  Conraads, Viviane ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Chronic heart failure; Cytokines; Inflammation; Tumour necrosis factor alpha

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; ETANERCEPT; IMMUNOGLOBULIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; NEUROHORMONE; PENTOXIFYLLINE; ROSUVASTATIN; SIMVASTATIN; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

CIRCULATION; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DISEASE SEVERITY; DRUG EFFECT; HEART FAILURE; HUMAN; IMMUNOMODULATION; ISCHEMIC HEART DISEASE; MYOCARDITIS; NONHUMAN; REVIEW; TISSUE LEVEL;

CHRONIC DISEASE; CYTOKINES; HEART FAILURE, CONGESTIVE; HUMANS; RECEPTORS, CYTOKINE;

EID: 33646008539     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.61.2.2014329     Document Type: Review

References (68)

1. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236-41.
2. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, Cassani G, Visioli O. Tumor necrosis factor soluble receptor in patients with various degrees of congestive heart failure. Circulation 1995; 92: 1479-86.
3. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 1996; 27: 1201-6.
4. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, Niebauer J, Hooper J, Volk H, Coats AJS, Anker SD. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000; 102: 3060-7.
5. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure. An analysis of the cytokine database from vesnarinone trial (VEST). Circulation 2001; 103: 2055-9.
6. Aukrust P, Ueland T, Lien E, Bendtzen K, Müller F, Andreassen AK, Nordoy I, Aass H, Espevik T, Simonsen S, Froland SS, Gullestad L. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999; 83: 376-82.
7. MacEwan DJ. TNF ligands and receptors - a matter of life and death. Br J Pharmacol 2002; 135: 855-75.
8. Dibbs Z, Thornby J, White BG, Mann DL. Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. J Am Coll Cardiol 1999; 33: 1935-42.
9. Conraads VM, Bosmans JM, Vrints CJ. Chronic heart failure: an example of a systemic chronic inflammatory disease resulting in cachexia. Int J Cardiol 2002; 85: 33-49.
10. Conraads VM, Bosmans JM, Schuerwegh AJ, Goovaerts I, De Clerck LS, Stevens WJ, Bridts CH, Vrints CJ. Intracellular monocyte cytokine production and CD14 expression are up-regulated in severe vs. mild chronic heart failure. J Heart Lung Transplant 2005; 24: 854-9.
11. Tran T, Trial JA, Birdsall HH. Site and source of cytokine overexpression in heart failure: the role of immune activation (abstract). Circulation 2000; 102: II 415-6.
12. Habib FM, Springall DR, Davies GJ, Oakley CM, Yacoub MH, Polak JM. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 1996; 347: 1151-5.
13. Torre-Amione G, Stetson SJ, Youker KA, Durand JB, Radovancevic B, Delgado RM, Frazier OH, Entman ML, Noon GP. Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support: A potential mechanism for cardiac recovery. Circulation 1999; 100: 1189-93.
14. Munger MA, Johnson B, Amber IJ, Callahan KS, Gilbert EM. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996; 77: 723-7.
15. Petretta M, Condorelli GL, Spinelli L, Scopacasa F, de Caterina M, Leosco D, Vicario MLE, Bonaduce D. Circulating levels of cytokines and their site of production in patients with mild to severe chronic heart failure. Am Heart J 2000; 140: E28.
16. Tsutamoto T, Wada A, Matsumoto T, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Yamamoto T, Horie H, Sugimoto Y, Kinoshita M. Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. J Am Coll Cardiol 2001; 37: 2086-92.
17. Tsutamoto T, Wada A, Ohnishi M, Tsutsui T, Ishii C, Ohno K, Fujii M, Matsumoto T, Yamamoto T, Takayama T, Dohke T, Horie M. Transcardiac increase in tumor necrosis factor-alpha and left ventricular end-diastolic volume in patients with dilated cardiomyopathy. Eur J Heart Fail 2004; 6: 173-80.
18. Adams V, Jiang H, Yu J, Möbius-Winkler S, Fiehn E, Linke A, Weigl C, Schuler GM, Hambrecht R. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J Am Coll Cardiol 1999; 33: 959-65.
19. Gielen S, Adams V, Mobius-Winkler S, Linke A, Erbs S, Yu J, Kempf W, Schubert A, Schuler G, Hambrecht R. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol 2003; 42: 861-8.
20. Hambrecht R, Gielen S, Linke A, Fiehn E, Yu J, Walther C, Shoene N, Schuler G. Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: a randomized trial. JAMA 2000; 283: 3095-101.
21. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D, Mabuchi N, Sawaki M, Kinoshita M. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998; 31: 391-8.
22. Grossman GB, Rohde LE, Clausell N. Evidence for increased peripheral production of tumor necrosis factor-alpha in advanced congestive heart failure. Am J Cardiol 2001; 88: 578-81.
23. Niebauer J, Volk H, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, Poole-Wilson PA, Coats AJS, Anker SD. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999; 353: 1838-42.
24. Peschel T, Schonauer M, Thiele H, Anker SD, Schuler G, Niebauer J. Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur J Heart Feil 2003; 5: 609-14.
25. Conraads VM, Jorens PG, De Clerck LS, Van Saene HK, Ieven MM, Bosmans JM, Schuerwegh A, Bridts CH, Wuyts F, Stevens WJ, Anker SD, Rauchhaus M, Vrints CJ. Selective intestinal decontamination in advanced chronic heart failure: a pilot trial. Eur J Heart Fail 2004; 6: 483-91.
26. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D'Agostino RB. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003; 107: 1486-91.
27. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002; 91: 988-98.
28. Bryant D, Becker L, Richardson J, Shelton J, Franco F, Peshock R, Thrompson M, Giroir B. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1998; 97: 1375-81.
29. Anker SD, Volterrani M, Egerer KR, Felton CV, Kox WJ, Poole-Wilson PA, Coats AJS. Tumor necrosis factor alpha as a predictor of peak leg blood flow in patients with chronic heart failure. Q J Med 1998; 91: 199-203.
30. Agnoletti L, Curello S, Bachetti T, Malacarne F, Gaia G, Comini L, Volterrani M, Bonetti P, Parrinello G, Cadei M, Grigolato PG, Ferrari R. Serum from patients with severe heart failure down regulates eNOS and is proapoptotic: role of tumor necrosis factor alpha. Circulation 1999; 100: 1983-91.
31. Rossig L, Fichtlscherer S, Heeschen C, Berger J, Dimmeler S, Zeiher AM. The pro-apoptotic serum activity is an independent mortality predictor of patients with heart failure. Eur Heart J 2004; 25: 1620-5.
32. Harrington D, Anker SD, Chua TP, Webb-Peploe KM, Ponikowski PP, Poole-Wilson PA, Coats AJS. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol 1997; 30: 1758-64.
33. Massie BM, Simonini A, Sahgal P, Wells L, Dudley GA. Relation of systemic and local muscle exercise capacity to skeletal muscle characteristics in men with congestive heart failure. J Am Coll Cardiol 1996; 27: 140-5.
34. Drexler H, Riede U, Münzel T, König H, Funke E, Just H. Alterations of skeletal muscle in chronic heart failure. Circulation 1992; 85: 1751-9.
35. Hambrecht R, Fiehn E, Yu JT, Niebauer J, Weigl C, Hilbrich L, Adams V, Riede U, Schuler G. Effects of endurance training on mitochondrial ultrastructure and fiber type distribution in skeletal muscle of patients with stable chronic heart failure. J Am Coll Cardiol 1997; 29: 1067-73.
36. Sullivan MJ, Green HJ, Cobb FR. Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure. Circulation 1990; 81: 518-27.
37. Janssen SP, Gayan-Ramirez G, Van den Bergh A, Herijgers P, Maes K, Verbeken E, Decramer M. Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats. Circulation 2005; 111: 996-1005.
38. Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C, Mann DL. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999; 99: 3224-6.
39. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, Mann DL. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001; 103: 1044-7.
40. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109: 1594-602.
41. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107: 3133-40.
42. Anker SD, Coats AJS. How to RECOVER from RENAISSANCE? The signifance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002; 86: 123-30.
43. Aukrust P, Ueland T, Müller F, Andreassen AK, Nordoy I, Aas H, Kjekshus J, Simonsen S, Froland SS, Gullestad L. Elevated circulating levels of C-chemokines in patients with congestive heart failure. Circulation 1998; 97: 1136-43.
44. Damas JK, Gullestad L, Aass H, Simonsen S, Fjeld JG, Wikeby L, Ueland T, Eiken HG, Froland SS, Aukrust P. Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure - modulatory effect of intravenous immunoglobulin. J Am Coll Cardiol 2001; 39: 187-93.
45. Davey PP, Ashrafian H. New therapies for heart failure: is thalidomide the answer? QJM 2000; 93: 305-11.
46. Skudicky D, Bergemann A, Sliwa K, Candy G, Sareli P. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol. Circulation 2001; 103: 1083-8.
47. Gullestad L, Aass H, Fjeld JG, Wikeby L, Andrezssen AK, Ihlen H, Simonsen S, Kjekshus J, Nitter-Hauge S, Ueland T, Lien E, Froland SS, Aukrust P. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001; 103: 220-5.
48. Torre-Amione G, Sestier F, Radovancevic B, Young J. Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial. J Am Coll Cardiol 2004; 44: 1181-6.
49. Conraads VM, Bosmans JM, Schuerwegh AJ, De Clerck LS, Bridts CH, Wuyts FL, Stevens WJ, Vrints CJ. Association of lipoproteins with cytokines and cytokine receptors in heart failure patients. Differences between ischaemic versus idiopathic cardiomyopathy. Eur Heart J 2003; 24: 2221-6.
50. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002; 8: 216-24.
51. Rauchhaus M, Clark AL, Doehner W, Davos C, Bolger A, Sharma R, Coats AJ, Anker SD. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003; 42: 1933-40.
52. Rauchhaus M, Coats AJS, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000; 356: 930-3.
53. Conraads V, Bosmans J, Schuerwegh A, De Clerck L, Bridts C, Wuyts F, Stevens W, Vrints C. Effect of short-term treatment with pravastatin on cytokines and cytokine receptors in patients with chronic heart failure due to ischemic and non-ischemic disease. J Heart Lung Transplant 2005; 24: 1114-7.
54. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003; 108: 839-43.
55. Bristow MR, Saxon LA, Boehmer J, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-50.
56. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-49.
57. Hambrecht R, Fiehn E, Weigl C, Gielen S, Hamann C, Kaiser R, Yu J, Adams V, Niebauer J, Schuler G. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation 1998; 98: 2709-15.
58. Adamopoulos S, Coats AJ, Brunotte F, Arnolda L, Meyer T, Thompson CH, Dunn JF, Stratton J, Kemp GJ, Radda GK, Rajagopalan B. Physical training improves skeletal muscle metabolism in patients with chronic heart failure. J Am Coll Cardiol 1993; 21: 1101-6.
59. Giannuzzi P, Temporelli PL, Corra U, Tavazzi L. Antire-modeling effect of long-term exercise training in patients with stable chronic heart failure. Results of the exercise in left ventricular dysfunction and chronic heart failure (ELVD-CHF) trial. Circulation 2003; 108: 554-9.
60. Braith RW, Welsch MA, Feigenbaum MS, Kluess HA, Pepine CJ. Neuroendocrine activation in heart failure is modified by endurance exercise training. J Am Coll Cardiol 1999; 34: 1170-5.
61. Conraads VM, Beckers P, Vaes J, Martin M, Van Hoof V, De Maeyer C, Possemiers N, Wuyts FL, Vrints CJ. Combined endurance/resistance training reduces NT-proBNP levels in patients with chronic heart failure. Eur Heart J 2004; 25: 1797-805.
62. Conraads VM, Beckers P, Bosmans J, De Clerck LS, Stevens WJ, Vrints, CJ, Brutsaert DL. Combined endurance/resistance training reduces plasma TNF-alpha receptor levels in patients with chronic heart failure and coronary artery disease. Eur Heart J 2002; 23: 1854-60.
63. Larsen AI, Aukrust P, Aarsland T, Dickstein K. Effect of aerobic exercise training on plasma levels of tumor necrosis factor alpha in patients with heart failure. Am J Cardiol 2001; 88: 805-8.
64. Adamopoulos S, Parissis J, Karatzas D, Kroupis C, Georgiadis M, Karavolias G, Paraskevaidis J, Koniavitou K, Coats AJ, Kremastinos D. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure. J Am Coll Cardiol 2002; 39: 653-63.
65. Linke A, Adams V, Schulze PC, Erbs S, Gielen S, Fiehn E, Mobius-Winkler S, Schubert A, Schuler G, Hambrecht R. Antioxidative effects of exercise training in patients with chronic heart failure: increase in radical scavenger enzyme activity in skeletal muscle. Circulation 2005; 111: 1763-70.
66. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan S. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397-402.
67. Gullestad L, Kjekshus J, Damas JK, Ueland T, Yndestad A, Aukrust P. Agents targeting inflammation in heart failure. Expert Opin Investig Drugs 2005; 14: 557-66.
68. Aukrust P, Gullestad L, Ueland T, Damas JK, Yndestad A. Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications. Ann Med 2005; 37: 74-85.